Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a treatment for non–small cell lung cancer (NSCLC).
Garrett Melton
Advertisement
Articles by Garrett Melton
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Long-Acting Growth Hormone Analogs: Beyond Convenience to Individualized Care
2
Increasing Guideline-Directed Care Adherence in Peripheral Artery Disease
3
Real-World Registries vs Clinical Trials in Long-Acting Growth Hormone Therapy
4
How to Safely Treat Acne, Psoriasis, and Eczema During Pregnancy
5